TDZD-8 is a member of the class of thiadiazolidines that is 1,2,4-thiadiazolidine-3,5-dione which is substituted by a methyl group at position 2 and by a benzyl group at position 4. It is a non-ATP competitive inhibitor of glycogen synthase kinase 3beta (GSK3beta). An experimental compound which was being developed for the potential treatment of Alzheimer's disease. It has a role as an antineoplastic agent, a neuroprotective agent, an anti-inflammatory agent, an apoptosis inducer and an EC 2.7.11.26 (tau-protein kinase) inhibitor. It is a member of benzenes and a thiadiazolidine.
